From randomized trial to practice: Single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer

G. D. Aletti, D. Nordquist, L. Hartmann, M. Gallenberg, H. J. Long, W. A. Cliby

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Background: The objective of the study was to evaluate completion rates and toxic effects of an i.p. chemotherapy regimen in a cross-section of nonselected patients with ovarian cancer (OC). Patients and methods: All patients with stage IIIC OC consecutively operated at our institution from January 2006 to December 2007 were prospectively collected and analyzed. Results: Eighty-nine patients with stage IIIC OC optimally debulked were evaluated for this study. An i.p. port was primarily placed in 53 of 89 (60%), and i.p. chemotherapy was recommended in 55 patients. Reasons for not recommending i.p. chemotherapy in patients optimally debulked included postoperative complications (n = 7: 8%), poor nutritional/functional status (n = 5: 6%), and extensive surgery including bowel resection (n = 9: 10%). Thirty-three patients (33/55: 60%) recommended to receive i.p. chemotherapy-initiated i.p. treatment. Fifty-two percent of those beginning i.p. therapy (17/33) received three or more cycles with 36% (12/33) successfully completing six cycles. Reasons for discontinuation included grade 3-4 nephrotoxicity in 3 of 21 (14%), febrile neutropenia/sepsis in 3 of 21 (14%), port infection or malfunction in 8 of 21 (38%). Conclusions: The i.p. chemotherapy regimen used in a consecutive cohort of patients carries could be completed in only a small percentage of patients. Less toxic regimens with higher acceptability should be considered.

Original languageEnglish (US)
Pages (from-to)1772-1778
Number of pages7
JournalAnnals of Oncology
Volume21
Issue number9
DOIs
StatePublished - Feb 5 2010

Keywords

  • I.p. chemotherapy
  • Ovarian cancer
  • Quality of care
  • Toxicity

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'From randomized trial to practice: Single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer'. Together they form a unique fingerprint.

Cite this